Intravenous Immunoglobulin and Cytokines
Authors:
- 27 September 2007
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1110 (1) , 426-432
Abstract
The presence of natural autoantibodies against cytokines has been reported in healthy individuals. Because circulating cytokines may be implicated in the clinical outcome of numerous diseases, the mode of action of intravenous immunoglobulin (IVIg) (pooled from sera over a thousand normal individuals) may involve immunomodulation of the cytokine network. We review the anti‐cytokine effects of IVIg as well as the consequences of IVIg infusions on cytokine production. Furthermore, IVIg exerts therapeutic effects in autoimmune diseases and lymphoid malignancies. These two conditions have in common an overproduction of BAFF (for B‐cell‐activating factor of the TNF family). The presence of antibodies with BAFF and APRIL (a proliferation‐inducing ligand) specificity was investigated. We found that IVIg recognizes BAFF and APRIL and that IVIg binding prevents BAFF from exerting its antiapoptotic effect on B cells. These anti‐BAFF IgGs might prevent the deleterious effects of BAFF in B‐cell‐mediated autoimmune diseases.Keywords
This publication has 26 references indexed in Scilit:
- Targeting BAFF: Immunomodulation for autoimmune diseases and lymphomasPharmacology & Therapeutics, 2006
- Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparationsJournal of Allergy and Clinical Immunology, 2003
- Immunomodulatory action of intravenous immunoglobulinImmunology, 2002
- Neutralizing antibodies to granulocyte–macrophage colony‐stimulating factor, interleukin‐1α and interferon‐α but not other cytokines in human immunoglobulin preparationsImmunology, 2000
- Selective induction of interleukin‐1 receptor antagonist and interleukin‐8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)European Journal of Immunology, 1995
- Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptorsEuropean Journal of Immunology, 1995
- Anti‐Cytokine Nature of Natural Human Immunoglobulin: One Possible Mechanism of the Clinical Effect of Intravenous Immunoglobulin TherapyImmunological Reviews, 1994
- Binding of cytokines to pharmaceutically prepared human immunoglobulin.Journal of Clinical Investigation, 1993
- Immunologically active proteins in intravenous immunoglobulinThe Lancet, 1993
- ANTIBODIES TO HUMAN LEUCOCYTE INTERFERONS IN CANCER PATIENTSThe Lancet, 1983